Skip to content

TuHURA Biosciences, Inc. HURA Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.1B-43.5%
CTO
Citius Oncology, Inc.CTOR
-$3.83M-179%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$38.03M-5.9%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-$10.37M-25.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$75.36M+12.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$17.69M-87.1%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s operating cash flow?
TuHURA Biosciences, Inc. (HURA) reported operating cash flow of -$4.41M in Q1 2026.
How has TuHURA Biosciences, Inc.'s operating cash flow changed year-over-year?
TuHURA Biosciences, Inc.'s operating cash flow increased by 6.9% year-over-year, from -$4.74M to -$4.41M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.